Vosoritide FDA Approval Status
Last updated by Judith Stewart, BPharm on Sep 14, 2020.
FDA Approved: No
Generic name: vosoritide
Company: BioMarin Pharmaceutical Inc.
Treatment for: Achondroplasia
Vosoritide is an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) in development for the treatment of children with achondroplasia.
Development Timeline for vosoritide
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.